专家评述
讲者：陈誉
单位：福建省肿瘤医院
讲者：周军
单位：北京大学肿瘤医院
张剑+Abstract ID: LBA3000+Abstract ID: 3004+Abstract ID: 3001
讲者：张剑
单位：复旦大学附属肿瘤医院
李宁+Abstract ID: 5503+Abstract ID: LBA5511+Abstract ID: 5509
讲者：李宁
单位：深圳龙华新区中心医院
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).
讲者：谢赣丰
单位：西南医院(陆军军医大学第一附属医院)
讲者：杨宏英
单位：云南省肿瘤医院
Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3
讲者：吴剑挥
讲者：王峰
单位：中山大学肿瘤防治中心
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence follow
讲者：刘秀峰
单位：东部战区总医院
